Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV) from private equity investor Advent International in a Rs136.3bn ($1.6bn) deal.
The move bolsters Mankind Pharma鈥檚 position in the Indian women’s health and fertility drug market.
The deal will also aid Mankind Pharma in providing access to high-barrier products in critical care leveraging complex research and development (R&D) tech platforms.
BSV, with more than five decades of expertise in biopharmaceuticals, has an established presence with its in-house developed recombinant and niche biologic products.
The company’s branded product portfolio spans women’s health, fertility and critical care, with several leading brands in their respective therapy areas.
Mankind Pharma vice-chairman and managing director Rajeev Juneja stated: 鈥淏SV鈥檚 acquisition represents a pivotal milestone in Mankind鈥檚 journey, establishing us as a market leader in the Indian women鈥檚 health and fertility segment. We believe the women鈥檚 health and fertility segment has massive opportunity along with strong growth visibility globally, led by structural tailwinds.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData鈥淏SV’s established speciality R&D tech platforms with a complex portfolio across women鈥檚 health, fertility, critical care and [the] immunoglobulin segment perfectly aligns Mankind Pharma’s strategic vision to expand its footprint in high entry barrier portfolio. We are also delighted to welcome BSV鈥檚 2,500+ members to our Mankind family.鈥�
The acquisition includes BSV’s comprehensive portfolio in women’s health, covering the reproductive lifecycle from fertility to post-pregnancy.
Its significant portfolio in the fertility segment will aid in scaling in both Indian and international markets, especially with the increasing penetration of in vitro fertilisation (IVF) treatments.
Mankind Pharma CEO and whole-time director Sheetal Arora stated: 鈥淢ankind鈥檚 strategic acquisition of BSV with branded speciality pharma portfolio across India and emerging markets presents immense growth potential and will add to the existing growth velocity of Mankind.鈥�
